linjc16/ctgov huggingface dataset:
Improvement in Glycemic Response After Bariatric Surgery

Study Overview
=================
Brief Summary
-----------------
decipher the role of microbiota in glycemic response change after bariatric surgery

Detailed Description
-----------------
Despite the vast knowledge linking the gut microbiome to metabolism and the glucose response, the relation still remains unclear. hopefully, a deep understanding of the mechanisms underlying metabolic improvement following bariatric surgery will make it possible to identify targets for pharmacological intervention, which will reduce the need for surgery and its risks. Previous studies have characterized the microbiome after bariatric surgery, but most suffer from methodological limitations. The current study has the potential to be innovative and make a significant contribution to understanding the mechanisms involved in early metabolic improvement after bariatric surgery.

Official Title
-----------------
Improvement in Glycemic Response After Bariatric Surgery

Conditions
-----------------
Bariatric Surgery

Intervention / Treatment
-----------------
* Procedure: sleeve gastrectomy surgery
* Procedure: gastric bypass surgery
* Procedure: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: candidates of bariatric surgery or cholecystectomy age 18-70 male/female Exclusion Criteria: previous bariatric surgery type 1 diabetes antibiotic treatment 3 months prior to the study probiotic treatment 3 months prior to the study chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders any pathologic findings during endoscopy participants who will suffer from a post-operation complication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| sleeve gastrectomy surgery<br>participants undergoing sleeve gastrectomy surgery for weight reduction | Procedure: sleeve gastrectomy surgery<br>* participants undergoing sleeve gastrectomy surgery<br>|
| gastric bypass surgery<br>participants undergoing gastric bypass surgery for weight reduction | Procedure: gastric bypass surgery<br>* participants undergoing gastric bypass surgery<br>|
| cholecystectomy<br>participants undergoing cholecystectomy | Procedure: control<br>* cholecystectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic response | The glycemic response will be measured by taking a blood test (glucose) after 12 hours fast and a second blood test (glucose) after an OGTT(oral glucose tolerance test) of 50 g glucose | up to 4 years | 
| microbiota composition | The microbiota composition will be assessed using the stool samples of the participants. | up to 4 years |
Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Study Overview
=================
Brief Summary
-----------------
The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period

Official Title
-----------------
Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Drug: Ipilimumab


Participation Criteria
=================
Eligibility Criteria
-----------------
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: Age of 18 years or older on date of first dose of Ipilimumab Subjects who received at least 1 dose of Ipilimumab for the treatment of unresectable, recurrent or metastatic melanoma in Venezuela Exclusion Criteria: Subjects who received Ipilimumab as part of a clinical trial Subjects who received Ipilimumab for any indication other than local approval (ie, unresectable or metastatic melanoma)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Melanoma patients on Ipilimumab<br>All unresectable, recurrent or metastatic melanoma patients | Drug: Ipilimumab<br> <br> * Other names: Yervoy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Descriptive statistics of observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela |  | Up to 12 months of treatment |
Emergency Coronary Artery Bypass Graft in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
A retrospective study investigating the early outcome of emergency CABG post MI in patients who were operated at Saud Al Babtain Cardiac Center.

Detailed Description
-----------------
A retrospective study of surgical patients who underwent Coronary Artery Bypass Graft for Acute Myocardial Infarction between December 2013 and February 2018 determining outcomes on morbidity and mortality.

Official Title
-----------------
Emergency Coronary Artery Bypass Graft in Acute Myocardial Infarction

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with post cardiogenic shock who underwent CABG =/> 17 years old Exclusion Criteria: Patients other than post cardiogenic shock who underwent CABG or any cardiac surgeries <17 years old

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| STEMI and Emergency CABG | Evaluate patients the early outcome of emergency CABG post MI. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CABG
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique

Study Overview
=================
Brief Summary
-----------------
This study is proposed to explore the correlation between fatty content of fatty liver and the difference of CT attenuation value in men using dual-energy CT, and to set up a threshold for diagnosis of fatty liver.

Detailed Description
-----------------
This study is proposed to explore the correlation between fatty content of fatty liver and the difference of CT attenuation value in men using dual-energy CT, and to set up a threshold for diagnosis of fatty liver.

Official Title
-----------------
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique

Conditions
-----------------
Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hepatic tumor living liver donor Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
BRAF V600E Mutations In Papillary Thyroid Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Detailed Description
-----------------
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.

Official Title
-----------------
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma

Conditions
-----------------
Papillary Thyroid Carcinoma

Intervention / Treatment
-----------------
* Genetic: BRAF V600E POSITIVITY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with papillary thyroid cancer Exclusion Criteria: Patients who do not want to be a part of this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BRAF V600E POSITIVITY<br>This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor. | Genetic: BRAF V600E POSITIVITY<br>* BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BRAF V600E MUTATION |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
papillary thyroid carcinoma, BRAF V600E, poor prognosis, aggressive
Treatment of Wegener's Granulomatosis With Cyclophosphamide

Study Overview
=================
Brief Summary
-----------------
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.

Detailed Description
-----------------
The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy. Age Range: greater than 1 year

Official Title
-----------------
Treatment of Wegener's Granulomatosis With Cyclophosphamide

Conditions
-----------------
Vasculitis, Wegener's Granulomatosis

Intervention / Treatment
-----------------
* Drug: cyclophosphamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients greater than 1 year of age with the clinical and pathological diagnosis of WG whose illness presents a risk of permanent disability or death. Examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs. No women who are pregnant or intend to become pregnant. No patients who have known malignancies. Patients must be HIV negative.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cyclophosphamide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cyclophosphamide, Vasculitis, Prednisone, Granuloma, Wegener's Granulomatosis, Renal Biopsy
DNA Methylation and Urothelial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Many studies previously showed the significant association between urinary arsenic profiles and urothelial carcinoma (UC) risk and observed the increased UC risk in people with lower plasma folate and higher homocysteine than those with higher plasma folate and lower homocysteine. The investigators would expect to explore the interactions among global DNA methylation, one-carbon metabolic pathway factors, urinary arsenic profiles and UC.

Official Title
-----------------
Level of DNA Methylation in People With Urothelial Carcinoma

Conditions
-----------------
Urothelial Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of urothelial carcinoma The voluntary of participating the study Exclusion Criteria: Age smaller than 20 years Pregnant women Not willing to participate the study because of their personal reasons

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| urothelial carcinoma pateints<br> | |
| healthy controls<br>Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urothelial carcinoma | Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists. | one year |
Meta-analysis of Efficacy of Topotecan

Study Overview
=================
Brief Summary
-----------------
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix

Detailed Description
-----------------
Studies included in the meta-analysis were: GOG-0179, GOG-0204 & GOG-0169

Official Title
-----------------
Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix

Conditions
-----------------
Cervical Intraepithelial Neoplasia

Intervention / Treatment
-----------------
* Drug: paclitaxel
* Drug: cisplatin
* Drug: topotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Randomised Clinical Trials or systematic reviews or meta-analyses Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cisplatin<br> | Drug: cisplatin<br>* cisplatin monotherapy<br>|
| cisplatin + topotecan<br> | Drug: cisplatin<br>* cisplatin monotherapy<br>Drug: topotecan<br>* topotecan<br>|
| cisplatin + paclitaxel<br> | Drug: paclitaxel<br>* paclitacel<br>Drug: cisplatin<br>* cisplatin monotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  | 12 months |
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.

Detailed Description
-----------------
The prognosis of patients with primary central nervous system lymphoma (PCNSL) is poor. Recent studies have demonstrated that autologous hematopoietic stem cell transplantation (auto-HSCT) could improve the prognosis of these patients. However, the optimal conditioning regimen of auto-HSCT remains unclear. In this study, the investigators evaluated the safety and efficacy of BUCYE conditioning regimens in PCNSL undergoing auto-HSCT.

Official Title
-----------------
Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Conditions
-----------------
Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning

Intervention / Treatment
-----------------
* Drug: Busulfan (BU)
* Drug: Cyclophosphamide (CY)
* Drug: Etoposide (VP-16)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary central nervous system lymphoma patients Achieving CR or PR, then mobilizing and collecting of peripheral blood stem cells Exclusion Criteria: Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) Patients with any conditions not suitable for the trial (investigators' decision)

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BUCYE<br>For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2. | Drug: Busulfan (BU)<br>* Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.<br>Drug: Cyclophosphamide (CY)<br>* Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.<br>Drug: Etoposide (VP-16)<br>* Etoposide was administered at 15 mg/kg/day on days -3 to -2.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | overall survival (OS) | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS | disease-free survival (DFS) | 2 year | 
| relapse rate | relapse rate | 2 year | 
| TRM | transplant-related mortality (TRM) | 2 year |
Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Cryosurgery kills cancer cells by freezing them during surgery. PURPOSE: Phase I/II trial to study the effectiveness of cryosurgery in treating patients with unresectable primary liver cancer or liver metastases.

Detailed Description
-----------------
OBJECTIVES: I. Assess the safety and efficacy of liquid nitrogen necrosis of liver lesions using a commercially available intraoperative cryosurgical system, with placement of the cryoprobe and subsequent monitoring by high-resolution ultrasound. II. Use this technique on selected patients with surgically unresectable metastatic or primary liver cancer whose disease appears confined to the liver and who are potentially curable if all tumor in the liver can be destroyed. III. Quantitate the quality and duration of survival, identify recurrence of hepatic malignant disease, and identify any morbidity from the procedure. OUTLINE: Cryosurgery. Liquid nitrogen freezing of tumor using a cryoprobe placed and maintained under ultrasound guidance. PROJECTED ACCRUAL: 50 patients will be treated.

Official Title
-----------------
Cryosurgical Destruction of Surgically Incurable Liver Tumors

Conditions
-----------------
Liver Cancer, Metastatic Cancer

Intervention / Treatment
-----------------
* Procedure: cryosurgery


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Biopsy-proven metastatic or primary malignant disease of the liver No extrahepatic regional or distant metastases No primary tumors commonly associated with local spread or metastases to other sites, e.g.: Gastric cancer Pancreatic cancer Breast cancer Lung cancer Liver lesions considered unresectable because of location in relation to major vascular structures or involvement of multiple hepatic segments Tumor extent and location such that cryosurgery expected to destroy all tumor and render patient disease-free Tumor volume no greater than 50% of total hepatic volume on CT No more than 12 lesions PATIENT CHARACTERISTICS: Age: Over 21 Other: Overall health permitting safe laparotomy Blood/body fluid analyses and imaging/exams for tumor measurement within 1 month prior to registration PRIOR CONCURRENT THERAPY: Prior liver resection, radiotherapy, or chemotherapy allowed

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cryosurgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver metastases, localized unresectable adult primary liver cancer, recurrent adult primary liver cancer